Off-Label Isotretinoin in Dermatologic Conditions: Doses, Duration, and Data

Fiona E. Lovegrove

doi:10.58931/cdt.2025.63144

Authors

Fiona E. Lovegrove, MD, PhD, FRCPC, DERM Lovegrove Dermatology, London, ON, Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Probity Medical Research, Waterloo, ON

DOI:

https://doi.org/10.58931/cdt.2025.63144

Abstract

Isotretinoin, also known as 13-cis-retinoic acid, has been a mainstay in dermatologic practice since its introduction in the early 1980s. Approved by Health Canada for the treatment of severe acne vulgaris, including recalcitrant nodular acne and acne conglobata, isotretinoin has since been repurposed for a wide variety of other skin conditions. Early clinical trials using an average maximum dose of 1.2 mg/kg/day over a 16 week period demonstrated significant efficacy, with 95% of patients showing clinical improvement and 84% achieving complete clearance.

Traditional isotretinoin regimens involved an initial dose of 0.5 mg/kg/day for 2–4 weeks, followed by maintenance therapy ranging from 0.1–1 mg/kg/day (up to a maximum of 2 mg/kg/day) over a total course of 12–16 weeks. However, findings from a larger dose-ranging study highlighted that side effects such as
xerosis were dose-dependent, yet recurrence rates reached 42% in patients treated with 0.1 mg/kg/day, suggesting the need to carefully balance efficacy and side-effect risks when prescribing isotretinoin.

More recently, micronized isotretinoin formulations and a better understanding of its pharmacodynamics have led to more widespread use of low-dose regimens. These offer similar efficacy with fewer adverse effects, better tolerability, and improved adherence.

Author Biography

Fiona E. Lovegrove, MD, PhD, FRCPC, DERM, Lovegrove Dermatology, London, ON, Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Probity Medical Research, Waterloo, ON

Dr. Fiona Lovegrove is a board-certified dermatologist and the founder of Lovegrove Dermatology in London, Ontario. She completed her MD/PhD in infectious disease research at the University of Toronto where she also completed her dermatology residency. She is actively involved in clinical trials as an investigator within the Probity Medical Research network and contributes to medical education as an associate professor at Western University. Her clinical focus is on medical dermatology and emerging therapies, with a special interest in psoriasis, atopic dermatitis, and autoimmune bullous diseases.

References

ACCUTANE™ ™ ROCHE® (isotretinoin capsule, USP 10 mg, 40 mg). Hoffman-La Roche Limited, Mississauga, ON: Product Monograph. [updated May 16, 2025, cited July 13, 2025]. Available from: https://assets.roche.com/f/173850/x/b313eef47a/accutane_pm_e.pdf

Peck GL, Olsen TG, Butkus D, Pandya M, Arnaud-Battandier J, Gross EG, et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol. 1982;6(4 Pt 2 Suppl):735–745. doi:10.1016/s0190-9622(82)70063-5

Strauss JS, Rapini RP, Shalita AR, Konecky E, Pochi PE, Comite H, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol. 1984;10(3):490–496. doi:10.1016/s0190-9622(84)80100-0

Sadeghzadeh‐Bazargan A, Ghassemi M, Goodarzi A, Roohaninasab M, Najar Nobari N, Behrangi E. Systematic review of low‐dose isotretinoin for treatment of acne vulgaris: focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies. Dermatol Ther. 2021;34(1):e14438. doi:10.1111/dth.14438

Desai S, Friedman A. Isotretinoin for rosacea: a systematic review. JAAD Int. 2024;16:112–118. doi:10.1016/j.jdin.2024.04.009

Guo W, Zhu C, Stevens G, Silverstein D. Analyzing the efficacy of isotretinoin in treating dissecting cellulitis: a literature review and meta-analysis. Drugs RD. 2021;21(1):29–37. doi:10.1007/s40268-020-00335-y

Shahpar A, Nezhad NZ, Sahaf A, Ahramiyanpour N. A review of isotretinoin in the treatment of frontal fibrosing alopecia. J Cosmet Dermatol. 2024;23(6):1956–1963. doi:10.1111/jocd.16245

Olguin-García MG, Jurado-Santa Cruz F, Peralta-Pedrero ML, Morales-Sánchez MA. A double-blind, randomized, placebo-controlled trial of oral isotretinoin in the treatment of recalcitrant facial flat warts. J Dermatol Treat. 2015 ;26(1):78–82. doi:10.3109/09546634.2013.869302

Luque-Luna M, Gil-Lianes J, Pigem R. [Translated article] RF – Safety and efficacy of isotretinoin for moderate-to-severe seborrheic dermatitis. Actas Dermo-Sifiliográficas. 2025;116(2):T178–T179. doi:10.1016/j.ad.2024.11.016

Neubert U, Plewig G, Ruhfus A. Treatment of gram-negative folliculitis with isotretinoin. Arch Dermatol Res. 1986;278(4):307–313. doi:10.1007/BF00407743

Boer J, van Gemert MJP. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40(1):73–76. doi:10.1016/s0190-9622(99)70530-x

Goh MS, Magee J, Chong AH. Keratosis follicularis spinulosa decalvans and acne keloidalis nuchae. Australas J Dermatol. 2005;46(4):257–260. doi:10.1111/j.1440-0960.2005.00196.x

Rodriguez‐Garijo N, Querol‐Cisneros E, Tomas‐Velazquez A, Estenaga A, Moreno‐Artero E, Idoate MA, et al. Recalcitrant granulomatous periorificial dermatitis with good response to low‐dose oral isotretinoin. Pediatr Dermatol. 2019;36(6):980–981. doi:10.1111/pde.13969

Tagliolatto S, Santos Neto O de O, Alchorne MM de A, Enokihara MY. Sebaceous hyperplasia: systemic treatment with isotretinoin. An Bras Dermatol. 2015;90(2):211–215. doi:10.1590/abd1806-4841.20153192

Aksoy B, Hapa A, Mutlu E. Isotretinoin treatment for folliculitis decalvans: a retrospective case‐series study. Int J Dermatol. 2018 Feb;57(2):250–253. doi:10.1111/ijd.13874

Rogel-Vence M, Carmona-Rodríguez M, Herrera-Montoro V, González-Ruiz L, Cortina-de la Calle MP, Sánchez-Caminero MP. Lupus miliaris disseminatus faciei with complete response to isotretinoin. Dermatol Online J. 2021;27(1):13030/qt2c42p7q0.

Bartell H, Ransdell BL, Ali A. Tinea versicolor clearance with oral isotretinoin therapy. J Drugs Dermatol JDD. 2006;5(1):74–75.

Smith LA, Cohen DE. Successful long-term use of oral isotretinoin for the management of Morbihan disease: a case series report and review of the literature. Arch Dermatol. 2012;148(12):1395-1398. doi:10.1001/archdermatol.2012.3109

Kromer C, Sabat R, Celis D, Mössner R. Systemic therapies of pityriasis rubra pilaris: a systematic review. JDDG J Dtsch Dermatol Ges. 2019;17(3):243–259. doi:10.1111/ddg.13718

Dicken CH, Bauer EA, Hazen PG, Krueger GG, Marks JG, McGuire JS, et al. Isotretinoin treatment of Darier’s disease. J Am Acad Dermatol. 1982;6(4 Pt 2 Suppl):721–726. doi:10.1016/s0190-9622(82)80052-2

Chang LM, Reyes M. A case of harlequin ichthyosis treated with isotretinoin. Dermatol Online J. 2014;20(2):doj_21540.

Levine N, Moon TE, Cartmel B, Bangert JL, Rodney S, Dong Q, et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev. 1997;6(11):957-961

Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL Jr. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol. 1987;123(2):201–204.

Lippman SM, Meyskens FL. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med. 1987;107(4):499–502. doi:10.7326/0003-4819-107-4-499

Off-Label Isotretinoin in Dermatologic Conditions: Doses, Duration, and Data

Authors

DOI:

Abstract

Author Biography

Fiona E. Lovegrove, MD, PhD, FRCPC, DERM, Lovegrove Dermatology, London, ON, Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Probity Medical Research, Waterloo, ON

References

Downloads

Published

How to Cite

Issue

Section

Summary

Open Access

Licence